/C O R R E C T I O N — EPEMED/

PARIS, June 3, 2010 - In the news release, "EPEMED, the European Personalised Medicine
Association, Appoints Executive Director" issued on 3 Jun 2010 06:00 GMT,
by EPEMED over PR Newswire, we are advised by a representative of the
company that contact details have now been made public.

Complete, corrected release follows:

The personalised medicine association EPEMED, a European not-for-profit
organisation bringing together global forces in personalised medicine, has
today announced the appointment of Dr. Anne Bruinvels, an entrepreneur in
personalised healthcare, as Executive Director and board member. Dr. Bruinvels
will be responsible for growing the start-up organisation and, together with
the board of directors, for building its strategic framework in creating
guidance for all those involved in progressing personalised medicine with an
emphasis on European market challenges.

"I'm very pleased with the appointment of Dr. Anne Bruinvels
as Executive Director and board member of EPEMED," said Alain Huriez, MD,
Founder and President of EPEMED. "Her proven leadership and communication
skills in the personalised medicine field will benefit the association
greatly and I look forward to working with her to bring harmonisation and
education to the personalised medicine field in Europe. "

Dr. Anne Bruinvels stated, "I'm delighted to join EPEMED's
board and to lead the association to facilitate the development and
introduction of personalised medicine in Europe. I'm looking forward to
working with the different parties worldwide involved in making real progress
in this field."

To date, Europe is faced with a number of challenges to
successfully develop innovative and effective, personalised medicine
treatments. EPEMED's objectives are to develop

    1. A central point of communication for the different parties
       involved in progressing personalised medicine

    2. Optimal routes to deliver personalised medicine treatments
       to patients

    3. A greater understanding of the clinical development of
       personalised therapeutics through the creation and application of
       advanced diagnostic tests

Dr. Bruinvels started her work in personalised medicine more
than 10 years ago. She has previously founded Elixior, a personalised
healthcare advisory company and prior to that Curidium, a personalised
medicine company identifying companion diagnostics and therapeutics to treat
patients with central nervous system disorders. She was Curidium's CEO for
more than six years and raised several rounds of funding before taking the
company public on the AIM of the London Stock Exchange. Anne Bruinvels has
also worked in research for various pharmaceutical companies, including
SmithKline Beecham, Wyeth and Sandoz Pharma. She obtained her PhD
(neuroscience) from Utrecht University (the Netherlands) and her MSc
(pharmacy) from Groningen University (The Netherlands).

EPEMED is a recently formed, not-for-profit organisation. The
association was founded to address issues in personalised medicine that
confront the industry, regulators, payers & insurers as well as governments.
EPEMED aims to provide a platform for the harmonisation of personalised
medicine development and implementation across Europe, focussing on the
crucial role of diagnostics, to make personalised medicine a reality. The
organisation is directed by a dynamic and diverse group of leaders in the
personalised medicine field, who have great expertise in the application and
development of diagnostic tools to deliver improved patient care.

About Personalised Medicine

Recent innovations in molecular diagnostics have played an
important role in improving patient outcomes in a range of human diseases.
Jointly with personalised therapeutics, companion diagnostics form the field
of personalised medicine, where a person's clinical, genomic and
environmental information is used to more precisely select medication and
dose for each individual patient. The application of personalised medicine is
likely to improve patient care as well as lower healthcare costs.

EPEMED (c) 2010. All rights reserved.

For more information on EPEMED see www.epemed.org or contact:

    Halle 13, Bio Ouest - Ile de Nantes, 21 Rue La Noue Bras de Fer, 44200,
    Nantes, France, Email: info@epemed.org Tel.: +33(0)240-358-999;
    Fax: +33(0)240-356720;

    Anne Bruinvels, Executive Director,
    E-mail: abruinvels@epemed.org

    Alain Huriez, Chairman,
    E-mail: ahuriez@epemed.org

    Caroline Carmagnol, ALIZE RP,
    caroline@alizerp.com
    +33-6-64-18-99-59

For more information on EPEMED see www. epemed.org or contact: Halle 13, Bio Ouest - Ile de Nantes, 21 Rue La Noue Bras de Fer, 44200, Nantes, France, Email: info at epemed.org Tel.: +33(0)240-358-999; Fax: +33(0)240-356720; Anne Bruinvels, Executive Director, E-mail: abruinvels at epemed.org; Alain Huriez, Chairman, E-mail: ahuriez at epemed.org. Caroline Carmagnol, ALIZE RP, +33-6-64-18-99-59 , caroline at alizerp.com